Date Published
November 2013

Page Count 
96

Additional Info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.


 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR Bundle

Epigenetic: Emerging Targets, Available Technologies, Expert Interviews, and an Epigenetic Community Perspective - Table of Contents

Executive Summary

Part I: Epigenetic Background and Target Information

Chapter 1

  • What is epigenetics?
  • Histone modifications
    • Histone methyltransferases
    • Arginine methyltransferases (RMT)
    • Histone demethylases
    • Epigenetic readers

Part II: Targets in the Industry

Chapter 2

  • Constellation Pharmaceuticals
  • Company background
  • Areas of research
    • SWI/SNF
    • EZH2
    • DOT1L
    • BET bromodomains
  • Challenges encountered
  • Competitive advantage
  • Partnerships
  • Future endeavors
  • Interview with Robert Sims
    • Company background
    • Research objectives
    • Benefits and challenges
    • Future endeavors

Chapter 3

  • EpiTherapeutics
  • Company background
  • Areas of research
    • PLU1
    • FBXL10
    • GASC1
  • Chemistry platform
  • Challenges encountered
  • Competitive advantage
  • Partnerships and future endeavors
  • Interview with Martin Bonde
    • Company background
    • Areas of research
    • Chemistry platform
    • Challenges encountered
    • Competitive advantage
    • Partnerships
    • Future endeavors

Chapter 4

  • Epizyme Inc.
  • Company background
  • Areas of research
    • DOT1L
    • EZH2
  • Challenges encountered
  • Competitive advantage
  • Partnerships
  • Future endeavors
  • Interview with Jesse Smith
    • Background
    • Areas of research
    • Target validation
    • Use of biomarkers
    • Challenges encountered
    • Partnerships
    • Future endeavors

Part III: Rising Technologies and Company Strategies

Chapter 5

  • Active Motif
  • Company background
  • Chromatin Immunoprecipitation (ChIP) technology
  • Competitive advantage
  • Challenges encountered
  • Validating antibodies using ChIP, ChIP-chip, and ChIP-Seq
  • Partnerships and strategies
  • Future endeavors
  • Interview with Kyle Hondorp
    • Company background
    • Immunoprecipitation technology
    • Challenges encountered
    • Future endeavors
    • Partnerships and growth

Chapter 6

  • Cayman Chemical
  • Company background
  • Applications
    • Time-resolved fluorescence resonance energy transfer (TR-FRET) assays
    • S-adenosyl-L-methionine (SAM)-screener assays
  • Challenges encountered
  • Partnerships
  • Future outlook
  • Interview with Dr. Levi Blazer
    • Company background
    • Partnerships
    • Areas of research
    • Assays
    • Challenges encountered
    • Future endeavors

Chapter 7

  • Reaction Biology Corporation
  • Company background
  • Reaction Biology Corporation’s role in epigenetics
  • Competitive strategies
  • Partnerships
  • Future outlook
  • Interview with Haiching Ma
    • Company background
    • Areas of research
    • Partnerships
    • Future expectations

Part IV: Epigenetics in the Community

Chapter 8

  • Survey results
  • Areas of study
  • Market outlook
  • Partnerships

References 

About Cambridge Healthtech Institute